Trends in e-Cigarette Use in Adults in the United States, 2016-2018 | Tobacco and e-Cigarettes | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Sign In
Figure.  e-Cigarette Use Among Adults in the Behavioral Risk Factor Surveillance System, 2016 to 2018
e-Cigarette Use Among Adults in the Behavioral Risk Factor Surveillance System, 2016 to 2018

Trends in current e-cigarette use prevalence by age (A); trends in daily e-cigarette use by age (B), in which the proportion of current users (daily to current use ratio) increased from 2016 to 2018; and trends in e-cigarette prevalence by age (C), including current e-cigarette use prevalence among those who have never smoked. Error bars indicate 95% CIs.

Table.  Characteristics and Trends of e-Cigarette Use Prevalence Among Adults in the US, 2016-2018
Characteristics and Trends of e-Cigarette Use Prevalence Among Adults in the US, 2016-2018
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Research Letter
    September 8, 2020

    Trends in e-Cigarette Use in Adults in the United States, 2016-2018

    Author Affiliations
    • 1The Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Baltimore, Maryland
    • 2The American Heart Association Tobacco Regulation and Addiction Center, Dallas, Texas
    • 3Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland
    • 4Department of Medicine, Yale New Haven Hospital, New Haven, Connecticut
    • 5Department of Global Health, Boston University, Boston, Massachusetts
    JAMA Intern Med. 2020;180(10):1394-1398. doi:10.1001/jamainternmed.2020.2817

    e-Cigarettes are generally perceived to be less harmful than traditional cigarettes.1 A considerable public health challenge is their use among young adults who have never smoked and among vulnerable subgroups, including individuals with mental health conditions and pregnant women.2-4 The rapidly evolving e-cigarette market, outdated tobacco laws and regulations, and the recent outbreak of e-cigarette or vaping product use–associated lung injuries highlight the need for up-to-date data on e-cigarette use.

    Methods

    We analyzed 1 156 411 participants from the nationally representative Behavioral Risk Factor Surveillance System 2016-2018 with information on e-cigarette use, which was categorized as never, former, or current (daily/occasional) use.3,4 We defined sole e-cigarette users as those who never use combustible cigarettes but who currently use e-cigarettes. Participants self-reported demographic information, cigarette smoking status, chronic health conditions, and health-risk behaviors (other tobacco use, heavy alcohol use, marijuana use, and binge drinking, defined elsewhere4). Data were analyzed in October 2019.

    Sampling weights and methodology are described elsewhere.3,4 Current e-cigarette use prevalence was analyzed by year, and absolute differences in percentage prevalence were calculated. Trends across the years were tested using logistic regression with survey year as a continuous variable. In 2018, only 33 states had e-cigarette use documented; we therefore conducted subanalysis of trends in only these states. The data used were publicly available and deidentified; thus, this study was exempt from was institutional review board review based on the Federal Policy for the Protection of Human Subjects Revised Common Rule. The statistical software used was Stata version 15.1 (StataCorp).

    Results

    The weighted overall current e-cigarette use prevalence was 4.5% (95% CI, 4.4%-4.6%) in 2016, remained stable at 4.4% (95% CI, 4.3%-4.5%) in 2017, then increased to 5.4% (95% CI, 5.2%-5.6%) in 2018. This translates to approximately 11 200 000 adults using e-cigarettes in the US in 2016, 11 000 000 in 2017, and 13 700 000 in 2018. These trends were similar across sociodemographic subgroups (Table). The youngest age group (18-24 years) had the largest increase in prevalence, from 9.2% in 2016 to 15% in 2018, as did students, whose use increased from 6.3% in 2016 to 12% in 2018 (Figure, A). Among those who never smoked, there was a significant increase in prevalence of e-cigarette use from 1.4% in 2016 to 2.3% in 2018. Participants who participated in health-risk behaviors, including marijuana use, had higher increases in e-cigarette use prevalence compared with those who did not (Table).

    Daily and occasional use prevalence increased from 2016 to 2018, with the largest change observed among 18- to 24-year-olds. The proportion of current users who used e-cigarettes daily (daily to current use ratio) also increased (Figure, B). Among those who never smoked, current e-cigarette use prevalence increased from 1.4% in 2016 to 2.3% in 2018, translating to approximately 3 500 000 adults in 2016 and 5 800 000 adults in 2018. The group of 18- to 24-year-olds had the highest prevalence of sole use each year (Figure, C). Trends in e-cigarette use in the 50 states and 3 territories included in the Behavioral Risk Factor Surveillance System were heterogenous but showed generally similar trends; trend analysis in the 33 states with complete data were consistent with the overall findings of this study.

    Discussion

    Findings from this nationally representative sample of US adults, including state-level analysis, show stable e-cigarette use prevalence between 2016 and 2017, followed by a marked increase from 2017 to 2018. We observed a shift toward daily use and sole e-cigarette use, and a significant increase in use among younger adults, especially students.

    While our study is the largest analysis to date that assesses the trends in current e-cigarette and sole e-cigarette use in U.S. adults, it has a few limitations. All data were also self-reported, so we cannot exclude some misclassification and information bias. Additionally, social desirability and recall bias may have led to underreporting of e-cigarette use and cigarette smoking status.

    Previous studies report a strong association between exposure to e-cigarette marketing and its subsequent use.5 We speculate that increased e-cigarette advertisement expenditure over the years and increased social media presence correlates with increased e-cigarette use, especially in the youngest age group. The significant increase in daily e-cigarette use suggests that more users are becoming dependent on e-cigarettes rather than merely experimenting with them. This is concerning among younger adults because early use of e-cigarettes has been associated with subsequent cigarette smoking, as well as drug and alcohol use.6 The increase in e-cigarette use among individuals exhibiting other health-risk behaviors, particularly marijuana use, is concerning especially in light of the outbreak of e-cigarette, or vaping, product use–associated lung injuries that has been linked to the vaping of tetrahydrocannabinoids.

    Back to top
    Article Information

    Accepted for Publication: May 25, 2020.

    Corresponding Author: Michael J. Blaha, MD, MPH, Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, 600 N Wolfe St, Blalock 524D1 JHH, Baltimore, MD 21287 (mblaha1@jhmi.edu).

    Published Online: September 8, 2020. doi:10.1001/jamainternmed.2020.2817

    Author Contributions: Dr Obisesan had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

    Concept and design: Obisesan, Osei, Uddin, Dzaye, Mirbolouk, Blaha.

    Acquisition, analysis, or interpretation of data: All authors.

    Drafting of the manuscript: Obisesan, Osei, Uddin, Dzaye, Mirbolouk.

    Critical revision of the manuscript for important intellectual content: Obisesan, Osei, Uddin, Dzaye, Stokes, Blaha.

    Statistical analysis: All authors.

    Obtained funding: Dzaye, Blaha.

    Administrative, technical, or material support: Osei, Blaha.

    Supervision: Uddin, Dzaye, Mirbolouk, Blaha.

    Conflict of Interest Disclosures: Dr Uddin reported grants from the National Institutes of Health outside the submitted work. Dr Stokes reported grants from Johnson & Johnson Inc outside the submitted work. Dr Blaha reported grants from the US Food and Drug Administration and the American Heart Association during the conduct of the study; grants from the National Institutes of Health and Aetna Foundation, grants and personal fees from Amgen Foundation, and personal fees from Sanofi, Regneron, Novartis, Novo Nordisk, Bayer, Akcea, Zogenix, Tricida, and Gilead outside the submitted work. No other disclosures were reported.

    Funding/Support: This research was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health and the US Food and Drug Administration Center for Tobacco Products under awards P50HL120163 and U54HL120163.

    Role of the Funder/Sponsor: The National Institutes of Health and the US Food and Drug Administration had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

    Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the US Food and Drug Administration, or the American Heart Association.

    References
    1.
    Goniewicz  ML, Lingas  EO, Hajek  P.  Patterns of electronic cigarette use and user beliefs about their safety and benefits: an internet survey.   Drug Alcohol Rev. 2013;32(2):133-140. doi:10.1111/j.1465-3362.2012.00512.xPubMedGoogle ScholarCrossref
    2.
    Liu  B, Xu  G, Rong  S,  et al.  National estimates of e-cigarette use among pregnant and nonpregnant women of reproductive age in the United States, 2014-2017.   JAMA Pediatr. 2019;173(6):600-602. doi:10.1001/jamapediatrics.2019.0658PubMedGoogle ScholarCrossref
    3.
    Obisesan  OH, Mirbolouk  M, Osei  AD,  et al.  Association between e-cigarette use and depression in the Behavioral Risk Factor Surveillance System, 2016-2017.   JAMA Netw Open. 2019;2(12):e1916800. doi:10.1001/jamanetworkopen.2019.16800PubMedGoogle Scholar
    4.
    Mirbolouk  M, Charkhchi  P, Kianoush  S,  et al.  Prevalence and distribution of e-cigarette use among U.S. adults: Behavioral Risk Factor Surveillance System, 2016.   Ann Intern Med. 2018;169(7):429-438. doi:10.7326/M17-3440PubMedGoogle ScholarCrossref
    5.
    Pierce  JP, Sargent  JD, Portnoy  DB,  et al.  Association between receptivity to tobacco advertising and progression to tobacco use in youth and young adults in the PATH study.   JAMA Pediatr. 2018;172(5):444-451. doi:10.1001/jamapediatrics.2017.5756PubMedGoogle ScholarCrossref
    6.
    Silveira  ML, Conway  KP, Green  VR,  et al.  Longitudinal associations between youth tobacco and substance use in waves 1 and 2 of the Population Assessment of Tobacco and Health (PATH) study.   Drug Alcohol Depend. 2018;191:25-36. doi:10.1016/j.drugalcdep.2018.06.018PubMedGoogle ScholarCrossref
    ×